CORONARY ARTERY DISEASE AMONG DIABETIC AND NON-DIABETIC PATIENTS WITH END STAGE RENAL DISEASE

Figures & data

Table 1. Baseline Characteristics

Characteristic	Diabetic n = 84	Non-diabetic n = 74	p value
Age	56.1 ± 14.2	53.9 ± 9.5	ns
Male gender	55 (65%)	57 (77%)	ns
Body mass index	26.6 ± 4.8	25.0 ± 5.6	0.06
H/o angina pectoris	24 (29)	16 (22)	ns
H/o past MI	16 (19)	4 (5)	0.01
Hypertension	76 (90)	66 (89)	ns
H/o Smoking	23 (27)	21 (28)	ns
Family h/o IHD	13 (15)	2 (3)	0.006
Hypercholesterolemia	46 (55)	27 (37)	0.021
Periph. vasc. disease	15 (18)	6 (8)	0.07
Hemoglobin (mg/dl)	9.8 ± 1.8	9.7 ± 1.8	ns
Ser. Glucose (mmol/l)	12.2 ± 5.3	6.7 ± 1.7	< 0.0001
Ser. Creatinine	688 ± 220	851 ± 357	0.001
Ser. Potassium	4.7 ± 0.7	4.7 ± 0.7	ns
ECG
LVH	25 (30)	37 (50)	0.009
Abnormal ST segment	11 (13)	10 (14)	ns
Abnormal T waves	46 (55)	35 (47)	ns
Abnormal Q waves	12 (14)	1(1)	0.003

Figures in parenthesis represent percentages.

H/o = history of, MI = myocardial infarction, IHD = ischemic heart disease, Periph. vasc. = peripheral vascular, ECG = electrocardiogram, LVH = left ventricular hypertrophy.

Table 2. Ventriculographic and Coronary Angiographic Characteristics

Characteristic	Diabetic n = 84	Non-diabetic n = 74	p value
Coronary Disease	56(67)	41(55)	ns
Single vessel CAD	19 (23)	17 (23)	ns
Two vessel CAD	14 (17)	15 (20)	ns
Three vessel CAD	23 (27)	9 (12)	0.018
Normal coronaries	28 (33)	33 (45)	ns
LAD involvement	43 (51)	30 (41)	ns
LCx involvement	37 (44)	24 (32)	ns
RCA involvement	33 (39)	20 (27)	ns
Segments with CAD	2.0	1.4	0.050
LVEF (%) (mean ± SD)	60 ± 12.2	62 ± 11.0	ns
LVEDVI (ml) (mean ± SD)	94 ± 38	101 ± 30	ns
LVESVI (ml) (mean ± SD)	26 ± 20	38 ± 20	ns
Systolic blood pressure	165 ± 36	161 ± 32	ns
Diastolic blood pressure	77 ± 14	79 ± 15	ns

Figures in parenthesis represent percentages.

CAD = coronary artery disease, LVEF = left ventricular ejection fraction, LVEDVI = left ventricular end diastolic volume index, LVESVI = left ventricular end systolic volume index, SD = standard deviation.

Figure 1. Stenosed coronary segments in diabetic and non-diabetic patients with ESRD.